IPF Partners

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing novel treatments for medical conditions with significant unmet needs. The company has a diverse pipeline that addresses acute trauma, cancer, and inflammatory diseases. Its lead product, Traumakine, is an investigational intravenous formulation of interferon beta-1a, currently undergoing Phase III clinical trials for treating acute respiratory distress syndrome (ARDS). Another key candidate, Clevegen, is an immunotherapy designed to prevent tumor growth and metastasis by targeting immune suppressor molecules in tumors, and is in Phase I/II development. Additionally, Faron is developing D-ARDS, a diagnostic tool aimed at assessing ARDS severity and monitoring outcomes. The company collaborates with the MediCity unit of Turku University Medical School to enhance its research and development efforts. Founded in 2003, Faron Pharmaceuticals is committed to advancing innovative solutions in healthcare.

Patient21 operates a health platform focused on improving the doctor-patient connection, which they view as essential for effective healthcare. The company aims to modernize the healthcare experience by addressing the fragmented and outdated processes currently prevalent in the industry. By leveraging technology, Patient21 enhances dental clinics with management software that streamlines administrative tasks such as appointment scheduling and patient data management. They also provide electronic health records (EHR) to healthcare professionals, which helps improve diagnostic quality and reduce costs. Through these innovations, Patient21 seeks to facilitate better decision-making for both patients and physicians, ultimately promoting a more personalized and collaborative approach to healthcare.

Poxel is a biopharmaceutical company based in Lyon, France, focused on developing innovative drugs for metabolic diseases, with a primary emphasis on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Founded in 2009, Poxel's lead product is Imeglimin, an oral anti-diabetic candidate in Phase III clinical development that targets key organs affected by diabetes, such as the pancreas, liver, and muscles. The company is also advancing PXL770, an adenosine monophosphate-activated protein kinase enzyme in Phase IIa clinical trials for treating chronic metabolic diseases like NASH. Additionally, Poxel has licensing agreements for PXL007 (EYP001), an FXR agonist in Phase I study for hepatitis B and NASH, and PXL065, a mitochondrial pyruvate carrier inhibitor in Phase I clinical trials for NASH.

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing novel treatments for medical conditions with significant unmet needs. The company has a diverse pipeline that addresses acute trauma, cancer, and inflammatory diseases. Its lead product, Traumakine, is an investigational intravenous formulation of interferon beta-1a, currently undergoing Phase III clinical trials for treating acute respiratory distress syndrome (ARDS). Another key candidate, Clevegen, is an immunotherapy designed to prevent tumor growth and metastasis by targeting immune suppressor molecules in tumors, and is in Phase I/II development. Additionally, Faron is developing D-ARDS, a diagnostic tool aimed at assessing ARDS severity and monitoring outcomes. The company collaborates with the MediCity unit of Turku University Medical School to enhance its research and development efforts. Founded in 2003, Faron Pharmaceuticals is committed to advancing innovative solutions in healthcare.

Caresyntax develops a digital surgery platform that improves patient outcomes by analyzing large volumes of data from operating rooms. Its proprietary software and AI enable OR teams to predict and enhance surgical performance, helping surgeons benchmark their care, hospital administrators optimize resources, medical device companies advance products, and insurance providers assess risk.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and previously known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. The platform enables healthcare providers to unify clinical and administrative workflows, automate tasks, and deliver measurable care, addressing the underlying systems that drive healthcare transformation. Lumeon's clientele includes some of Europe's leading healthcare providers, such as BUPA and Nuffield Health, reflecting its position as a key player in the market. The company employs over 90 professionals dedicated to enhancing patient care through effective management and analysis of healthcare pathways.

Caresyntax develops a digital surgery platform that improves patient outcomes by analyzing large volumes of data from operating rooms. Its proprietary software and AI enable OR teams to predict and enhance surgical performance, helping surgeons benchmark their care, hospital administrators optimize resources, medical device companies advance products, and insurance providers assess risk.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and previously known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. The platform enables healthcare providers to unify clinical and administrative workflows, automate tasks, and deliver measurable care, addressing the underlying systems that drive healthcare transformation. Lumeon's clientele includes some of Europe's leading healthcare providers, such as BUPA and Nuffield Health, reflecting its position as a key player in the market. The company employs over 90 professionals dedicated to enhancing patient care through effective management and analysis of healthcare pathways.

SpineGuard is a French medical company specializing in radiation-free real-time sensing technology for orthopedic surgery. Its flagship product, PediGuard probes, assist spine surgeons in accurately placing pedicle screws during spinal procedures. With over 80,000 successful procedures worldwide and extensive clinical evidence, SpineGuard's devices are becoming a standard solution for safe and accurate pedicle screw placement.

Genesis Automation develops a clinical traceability platform designed to improve patient safety and operational efficiency in healthcare. The platform tracks the movement of critical supplies and equipment from manufacturer to point of care, enabling hospitals and suppliers to verify that patients receive the correct medications and devices, while enhancing supply chain visibility, reducing waste, and cutting costs across the healthcare value chain.

Genesis Automation is a single source, full-service automated system solutions provider. It designs and builds high-precision assembly, test, and special process equipment for a wide range of industries. Genesis Automation was founded in 1999 and is based in Cork, Ireland.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and previously known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. The platform enables healthcare providers to unify clinical and administrative workflows, automate tasks, and deliver measurable care, addressing the underlying systems that drive healthcare transformation. Lumeon's clientele includes some of Europe's leading healthcare providers, such as BUPA and Nuffield Health, reflecting its position as a key player in the market. The company employs over 90 professionals dedicated to enhancing patient care through effective management and analysis of healthcare pathways.

Mauna Kea Technologies is a medical device company that develops, manufactures and markets imaging solutions for real-time cellular-level visualization during minimally invasive procedures to improve cancer and other disease diagnosis and treatment. Its flagship Cellvizio platform combines a probe-based endomicroscopy system that provides in vivo cellular images during procedures, enabling clinicians to assess tissue at the microscopic level in real time. The company serves customers globally, with products cleared or approved in the United States and more than 40 countries, and operates across Europe, the Middle East, Africa, the Americas, and Asia. Mauna Kea aims to eliminate uncertainties in diagnosis and treatment by visualizing tissue in vivo during standard procedures.

Impeto Medical SAS is a privately owned medical device company established in June 2005, with its headquarters located in Paris, France, and additional subsidiaries in China and San Diego, California. The company specializes in the manufacture and marketing of non-invasive diagnostic devices that assess eccrine sweat gland activity. Its product lineup includes SUDOSCAN+, which is used for detecting and monitoring peripheral autonomic neuropathy; EZSCAN, designed for screening and preventing diabetes and cardio metabolic risks; and SUDOSCAN, a device that evaluates galvanic skin response to assess sympathetic nervous system behavior in various conditions, including diabetes and Parkinson's disease. Impeto Medical's innovative technology enables healthcare professionals to screen large patient populations effectively, facilitating early detection of metabolic disorders and related complications. The company distributes its products through a network of distributors.

Neuravi Limited, established in 2009 and based in Galway, Ireland, specializes in designing and developing medical devices for treating acute ischemic strokes. The company's primary product, the EmboTrap revascularization device, is designed to restore blood flow by removing clots from blocked brain arteries. Neuravi operates in multiple European countries and is a subsidiary of DePuy Ireland Unlimited Company.

Founded in 2013, Cassini Technologies is a Dutch medical device company specializing in developing innovative corneal diagnostic solutions. It pioneers smart and superior eye diagnosis tools like the Cassini Corneal Shape Analyzer and EasyScan retinal imaging system, empowering care providers worldwide to serve their patients better.

Genesis Automation develops a clinical traceability platform designed to improve patient safety and operational efficiency in healthcare. The platform tracks the movement of critical supplies and equipment from manufacturer to point of care, enabling hospitals and suppliers to verify that patients receive the correct medications and devices, while enhancing supply chain visibility, reducing waste, and cutting costs across the healthcare value chain.

SpineGuard is a French medical company specializing in radiation-free real-time sensing technology for orthopedic surgery. Its flagship product, PediGuard probes, assist spine surgeons in accurately placing pedicle screws during spinal procedures. With over 80,000 successful procedures worldwide and extensive clinical evidence, SpineGuard's devices are becoming a standard solution for safe and accurate pedicle screw placement.

Mainstay Medical is a medical device company focused on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat chronic mechanical low back pain by restoring control to the lumbar stabilizing muscles. Headquartered in Dublin, Ireland, it operates in Ireland, the United States, and Australia and collaborates with scientists and clinical experts to deliver therapies for the large underserved population of people with debilitating chronic low back pain. Founded in 2008, the company aims to provide a restorative treatment that improves function and quality of life by reestablishing muscle control in the lumbar spine.

Founded in 2013, Cassini Technologies is a Dutch medical device company specializing in developing innovative corneal diagnostic solutions. It pioneers smart and superior eye diagnosis tools like the Cassini Corneal Shape Analyzer and EasyScan retinal imaging system, empowering care providers worldwide to serve their patients better.

EOS Imaging SA is a medical technology company based in Paris, France, specializing in low-dose 2D/3D imaging and software solutions for osteo-articular conditions and orthopedic surgeries. The company develops and markets the EOS imaging system, which produces full-body, stereo-radiographic images of patients in functional positions, tailored to the specific needs of orthopedic surgeons and radiologists. Its product offerings include EOSedge, a high-quality X-ray system, sterEOS, a 3D modeling workstation for precise skeletal analysis, and EOSapps, online surgical planning solutions based on real-time imaging. Additionally, EOS Imaging creates planning software for knee and hip surgeries and manufactures patient-specific cutting guides for orthopedic procedures. The company operates globally, with a presence in Europe, the Middle East, Africa, North America, the Asia-Pacific, and Latin America, and has obtained marketing authorization for its systems in 48 countries. Founded in 1989, EOS Imaging was previously known as biospace med before rebranding in 2010.

Mendor is a Finnish company focused on the design, development, and marketing of advanced diabetes management products. It has introduced an innovative all-in-one blood glucose meter and a web-based software application that simplify daily diabetes management. These products are developed in collaboration with users and diabetes experts, ensuring they meet the specific needs of individuals requiring regular blood glucose monitoring. Mendor's patented software systems deliver real-time diabetes care data, enhancing the efficiency and effectiveness of treatment for patients and caregivers alike.

BONESUPPORT AB is a medical technology company based in Lund, Sweden, specializing in the development of injectable bioceramic bone graft substitutes aimed at treating fractures and bone voids resulting from trauma, infection, disease, or surgery. Founded in 1999, the company offers a range of products, including CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V. These products are designed to address various medical conditions such as chronic osteomyelitis and infected diabetic foot ulcers. CERAMENT G and CERAMENT V are antibiotic-eluting bone graft substitutes that enhance bone healing, utilizing gentamicin and vancomycin, respectively. BONESUPPORT operates additional locations in Frankfurt, Zurich, London, Boston, and Haryana, India, and is committed to improving the quality of life for patients with bone disorders through innovative biomaterial solutions.